Introduction

Company name: Fort Dodge Animal Health

Address: Flanders Road

Hedge End

Southampton SO30 4QH

Telephone: 01489 781711

Fax: 01489 788306

Presentation

One vial of freeze dried fraction containing live attenuated strains of feline rhinotracheitis virus, strain 2112 (104.5 to 106.7 TCID50), feline calicivirus, strain 2113 (105.5 to 107.7 TCID50) and feline panleucopenia virus, strain E (105.0 to 107.3 HAID50)and one vial of sterile diluent for veterinary use.

Uses

For the active immunisation of cats and kittens to reduce mortality and clinical signs caused by feline rhinotracheitis virus; to reduce clinical signs due to feline calicivirus; to prevent mortality and clinical signs and reduce the adverse effects on the immune system caused by feline panleucopenia virus infection.

The onset of immunity is from two weeks after the second vaccination. The duration of immunity is at least one year for all three antigens.

Dosage and administration

The vaccine is to be administered subcutaneously to cats of 9 weeks of age or older.

Aseptically reconstitute the contents of the freeze-dried vial using 1 ml sterile diluent or Fevaxyn FeLV as a diluent.

Primary vaccination:

A single dose of Katavac CHP should be administered from 9 weeks of age followed by a second injection after an interval of 3-4 weeks.

Booster vaccination:

Booster vaccinations are recommended every 12 months.

Field experience indicates that a single vaccination can be expected to be sufficient as an annual booster.

Contra-indications, warnings, etc

Do not vaccinate sick cats.

Do not vaccinate pregnant queens.

No information is available on the effects of concurrent use of this vaccine with any other except Fevaxyn FeLV. It is therefore recommended that no other vaccine than this should be administered within 14 days before or after vaccination with this product.

Do not mix with any other vaccine/immunological product except the sterile diluent provided or Fevaxyn FeLV.

Very occasional lethargy, coughing, sneezing, localised swelling and pain have been observed in cats in the field, however, the incidence of these cases is rare.

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

In case of accidental self-injection/ingestion/spillage on to skin, seek medical advice immediately and show the package insert or label to the physician.

Pharmaceutical precautions

Keep out of the reach and sight of children.

Store and transport refrigerated (+2°C to +8°C). Do not freeze. Protect from light.

Legal category

POM-V

Packaging Quantities

10, 25 and 50 × 1 ml doses. Each dose is a combination of one vial of freeze-dried fraction and one vial of sterile diluent.

Not all pack sizes may be marketed.

Further information

For Animal Treatment Only

The effect of higher levels of maternally derived antibodies on the response to vaccination is not known. However, on the basis of field use, it is expected that in the majority of cats, the levels of maternally derived antibodies that will be present at 9 weeks of age will not interfere with the response to vaccination.

The live vaccine strains may spread to unvaccinated animals, but do not cause the disease.

In any animal population there will be a small number of individuals which fail to respond fully to vaccination. Successful vaccination depends upon correct storage and administration of the vaccine and the animal's ability to respond. Immune competence can be influenced by genetic factors, intercurrent infection, age, nutritional status, concurrent drug therapy, stress, etc.

Disposal:

Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.

Marketing authorisation number

Vm 01596/4362